Gland Pharma Gets US FDA Nod for Generic Sugammadex Injection
Source: ET Real Estate
Arth Insight · What this means for your wallet
- Gland Pharma's generic sugammadex injection approved by USFDA.
- The drug reverses muscle relaxant effects used in surgery.
- The generic is bioequivalent to Merck's BRIDION injection.
Wealth-Impact Simulator
See how a change in interest rates hits your loan EMI.
Indicative estimate for education only — not investment advice.
Compare loan ratesGland Pharma has received US FDA approval for its generic version of sugammadex injection, a drug used to reverse muscle relaxants during surgery. This approval marks a significant step for the company in the US market.
- ▸Gland Pharma's generic sugammadex injection approved by USFDA.
- ▸The drug reverses muscle relaxant effects used in surgery.
- ▸The generic is bioequivalent to Merck's BRIDION injection.
- ▸This approval could boost Gland Pharma's US market presence.
- ✓Gland Pharma's generic sugammadex injection approved by USFDA.
- ✓The drug reverses muscle relaxant effects used in surgery.
- ✓The generic is bioequivalent to Merck's BRIDION injection.
- ✓This approval could boost Gland Pharma's US market presence.
Gland Pharma has secured approval from the United States Food and Drug Administration (USFDA) for its generic sugammadex injection. This drug plays a crucial role in surgical procedures by reversing the effects of muscle relaxants administered to patients.
The USFDA approval covers two specific strengths of the single-dose vial product. The newly approved generic injection is bioequivalent to Merck's original BRIDION injection, indicating comparable efficacy and safety. The market for sugammadex injection in the US has shown significant sales in the past year, suggesting a substantial demand for such pharmaceutical products.
This development is a positive step for Gland Pharma, potentially expanding its product portfolio and market reach in the United States. The company's ability to bring generic versions of critical drugs to market highlights its manufacturing capabilities and its role in making healthcare more accessible.
This report is for informational purposes only and does not constitute investment advice.
Community Pulse · This story
How readers rate the outlook after reading this article. Anonymous · one vote per reader · updates live.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What is sugammadex injection used for?
Sugammadex injection is used to reverse the effects of muscle relaxant drugs that are administered during surgical procedures.
Which company's product is Gland Pharma's generic equivalent to?
Gland Pharma's generic sugammadex injection is bioequivalent to Merck's BRIDION injection.
What does USFDA approval signify?
USFDA approval means the drug has met the stringent safety and efficacy standards set by the United States Food and Drug Administration, allowing it to be marketed and sold in the US.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
AstraZeneca Shares Dip as Breast Cancer Drug Etcamah Fails Key Late-Stage Trial
AstraZeneca's breast cancer treatment, Etcamah, failed to meet its primary goal in a late-stage clinical trial when combined with palbociclib. The setback led to a decline in the company's US-listed shares during aftermarket trading.
Zillow: Global Homebuyers Reduce Activity as Mortgage Rates Climb
A global report by Zillow, cited by Yahoo Finance, indicates a significant slowdown in homebuying activity. This decline is attributed to rising mortgage rates, which are making home loans more expensive for prospective buyers worldwide.
BreakingBlackstone Exits Indian Real Estate, Sells Assets Worth Up to ₹10,800 Crore
Global investment firm Blackstone has reportedly sold Indian real estate assets valued at up to ₹10,800 crore (approximately $1.3 billion). This significant transaction marks a partial exit from its long-standing real estate investments in India, underscoring its strategy to capitalize on profitable ventures.
Related Stories
AstraZeneca Shares Dip as Breast Cancer Drug Etcamah Fails Key Late-Stage Trial
AstraZeneca's breast cancer treatment, Etcamah, failed to meet its primary goal in a late-stage clinical trial when combined with palbociclib. The setback led to a decline in the company's US-listed shares during aftermarket trading.
Zillow: Global Homebuyers Reduce Activity as Mortgage Rates Climb
A global report by Zillow, cited by Yahoo Finance, indicates a significant slowdown in homebuying activity. This decline is attributed to rising mortgage rates, which are making home loans more expensive for prospective buyers worldwide.
BreakingBlackstone Exits Indian Real Estate, Sells Assets Worth Up to ₹10,800 Crore
Global investment firm Blackstone has reportedly sold Indian real estate assets valued at up to ₹10,800 crore (approximately $1.3 billion). This significant transaction marks a partial exit from its long-standing real estate investments in India, underscoring its strategy to capitalize on profitable ventures.
BreakingBad Tenant Costs 45-Year-Old Landlord ₹23.2 Lakh; Is Rental Property Still a Good Bet?
A 45-year-old landlord suffered a significant financial loss of approximately ₹23.2 lakh due to a problematic tenant, covering unpaid rent, legal expenses, and repair costs. Despite this experience, his friends encourage him to invest in another rental property, sparking a debate on the risks versus rewards of real estate investment.